Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. (Q47968070)

7 February 2018

title

Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. (English)

1 reference

7 February 2018

1 reference

1 reference

chronic heart failure

1 reference

12

1 reference

7 February 2018

Stefan D. Anker

2

object named as

Stefan D Anker

1 reference

7 February 2018

13

Jean Lucien Rouleau

1 reference

7 February 2018

Michael Motro

8

object named as

Michael Motro

1 reference

7 February 2018

author name string

Guillermo Torre-Amione

1

1 reference

7 February 2018

Robert C Bourge

3

1 reference

7 February 2018

Wilson S Colucci

4

1 reference

7 February 2018

Barry H Greenberg

5

1 reference

7 February 2018

Per Hildebrandt

6

1 reference

7 February 2018

Andre Keren

7

1 reference

7 February 2018

Lemuel A Moyé

9

1 reference

7 February 2018

Jan Erik Otterstad

10

1 reference

7 February 2018

Craig M Pratt

11

1 reference

7 February 2018

Francois Sestier

14

1 reference

7 February 2018

Bernhard R Winkelmann

15

1 reference

7 February 2018

James B Young

16

1 reference

7 February 2018

Advanced Chronic Heart Failure CLinical Assessment of Immune Modulation Therapy Investigators

17

1 reference

7 February 2018

language of work or name

English

0 references

publication date

1 January 2008

1 reference

7 February 2018

published in

The Lancet

1 reference

7 February 2018

volume

371

1 reference

7 February 2018

issue

9608

1 reference

7 February 2018

page(s)

228-236

1 reference

7 February 2018

Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960134-8

7 January 2021

Inflammatory mediators and the failing heart: past, present, and the foreseeable future

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960134-8

7 January 2021

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960134-8

7 January 2021

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960134-8

7 January 2021

A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960134-8

7 January 2021

Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960134-8

7 January 2021

Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960134-8

7 January 2021

Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960134-8

7 January 2021

Immunosuppressive effects of apoptotic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960134-8

7 January 2021

Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960134-8

7 January 2021

Effects of VasoCare therapy on the initiation and progression of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960134-8

7 January 2021

The effect of VAS972 on allergic contact hypersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960134-8

7 January 2021

Attenuation of LPS-induced changes in synaptic activity in rat hippocampus by Vasogen's Immune Modulation Therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960134-8

7 January 2021

Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960134-8

7 January 2021

A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: the ACCLAIM trial rationale and design

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960134-8

7 January 2021

Increased circulating cytokines in patients with myocarditis and cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960134-8

7 January 2021

Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960134-8

7 January 2021

Biologic effects and basic science of a novel immune-modulation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960134-8

7 January 2021

Association between serum values of C-reactive protein and cytokine production in whole blood of patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960134-8

7 January 2021

Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960134-8

7 January 2021

Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960134-8

7 January 2021

The effect of etanercept on cardiac transplant recipients: a study of TNFalpha antagonism and cardiac allograft hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2960134-8

7 January 2021

10.1016/S0140-6736(08)60134-8

Identifiers

DOI

1 reference

7 February 2018

PubMed ID

18207018

1 reference

7 February 2018